Geode Capital Management
BRNS

Geode Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

Geode Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.62K Hold
11,568
– – ﹤0.01% 4497
2025
Q4 		$8.1K Hold
11,568
– – ﹤0.01% 4441
2025
Q3 		$14.5K Hold
11,568
– – ﹤0.01% 4436
2025
Q2 		$10.5K Hold
11,568
– – ﹤0.01% 4416
2025
Q1 		$11.5K Hold
11,568
– – ﹤0.01% 4426
2024
Q4 		$13.9K Hold
11,568
– – ﹤0.01% 4417
2024
Q3 		$14.2K Hold
11,568
– – ﹤0.01% 4435
2024
Q2 		$16.2K Hold
11,568
– – ﹤0.01% 4485
2024
Q1 		$27.8K Hold
11,568
– – ﹤0.01% 4432
2023
Q4 		$41.2K Buy
+11,568
New +$39.1K ﹤0.01% 4397

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Geode Capital Management's BRNS Position: Q1 2026 in Review

Geode Capital Management held its Barinthus Biotherapeutics (BRNS) position steady in Q1 2026 at 11,568 shares worth $6.62K. The position accounts for ﹤0.01% of the portfolio, ranked #4497.

Geode Capital Management first reported a position in BRNS in Q4 2023 and has held it in 10 quarters since. The position peaked at $41.2K in Q4 2023. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • Geode Capital Management held 11,568 shares of Barinthus Biotherapeutics worth $6.62K as of Q1 2026.
  • Geode Capital Management left its Barinthus Biotherapeutics share count unchanged in Q1 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4497 holding.
  • Geode Capital Management first reported a position in Barinthus Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
  • Geode Capital Management's Barinthus Biotherapeutics position peaked at $41.2K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.